Ignis Therapeutics, founded in 2020 and headquartered in Shanghai, China, is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for central nervous system (CNS) disorders. With a robust pipeline featuring FDA-approved drugs like cenobamate, for partial-onset seizures, and solriamfetol, for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, Ignis is committed to transforming treatment paradigms through cutting-edge neuroscience research. Its pipeline also includes several IND granted/preclinical assets, and one in-house Prismal discovery platform enabling the development of multiple innovative pipelines covering epilepsy, ADHD, schizophrenia, major depression disorder, and Parkinson’s disease. Backed by $180 million in Series A funding from major investors like 6Dimension, including HBM Healthcare Investments and SK Biopharmaceuticals, operates state-of-the-art R&D and GMP manufacturing facilities in Shanghai and Suzhou.